Medically Reviewed by Dr. Michael Nguyen, PharmD, BSPharm — Functional Medicine Pharmacist, Sterile Compounding Specialist, PCCA & NHIA Certified. 27+ years of clinical experience in peptide therapy and metabolic health.
Key Takeaways
- › Retatrutide (LY3437943) is the first triple agonist to simultaneously activate GLP-1, GIP, and glucagon receptors — producing weight loss results no single or dual agonist has matched.
- › Phase 2 trials showed up to −24.2% body weight loss at 48 weeks. Phase 3 TRIUMPH-4 data (December 2025) showed −28.7% — roughly 71 lbs — at 68 weeks.
- › Retatrutide achieves approximately double the weight loss of semaglutide and meaningfully outperforms tirzepatide at comparable timeframes.
- › It reduces hepatic fat by up to 82% — uniquely powerful for patients with fatty liver (MASLD).
- › FDA approval is not yet granted. Provider-supervised access is available now through compounding programs. Baseline labs are essential before starting.
What Is Retatrutide and How Does It Work?
Retatrutide (development code LY3437943) is an investigational once-weekly injectable peptide developed by Eli Lilly. It belongs to a new class called triple agonists — meaning it simultaneously activates three separate hormone receptors: GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and glucagon.
If you’re familiar with semaglutide (Ozempic, Wegovy) — that’s a GLP-1 agonist. Tirzepatide (Mounjaro, Zepbound) adds GIP on top. Retatrutide adds a third mechanism: glucagon receptor activation. Each receptor contributes something distinct to the weight loss effect.
GLP-1 activation reduces appetite, slows gastric emptying, and improves insulin sensitivity — the same pathway targeted by Ozempic and Wegovy. GIP activation amplifies the insulin and satiety response and enhances the GLP-1 effect at the brain level — the same advantage that makes tirzepatide outperform semaglutide. Glucagon activation is what makes retatrutide categorically different: it directly increases energy expenditure through thermogenesis and drives the liver to oxidize fat directly. No currently approved medication targets this receptor.
The result is a compound that doesn’t just suppress appetite. It simultaneously reduces caloric intake, increases caloric burn, and forces the liver to process fat more aggressively — all three levers of metabolism pulled at once.
Dr. Nguyen’s perspective: In 27 years of working with metabolic patients, I’ve watched GLP-1 therapy evolve from a modest appetite suppressant to semaglutide’s meaningful weight loss, then to tirzepatide’s dual mechanism. Retatrutide’s glucagon component is the first genuinely new mechanistic layer in this class. It addresses the energy expenditure side of the equation that every prior drug left largely untouched.
[INTERNAL-LINK: how peptide therapy works → pillar page on peptide therapy for weight loss]
Retatrutide: The Biological Reset Beyond Fat Loss
Watch more on our YouTube channel ›
What the Clinical Trials Show
The landmark Phase 2 trial published in the New England Journal of Medicine enrolled 338 adults with obesity across 48 weeks (Jastreboff et al., PMID 37366315). At the 12 mg dose, 100% of participants lost at least 5% of body weight, 93% lost at least 10%, and 83% lost at least 15%. No drug in this class has ever produced that level of response consistency in a Phase 2 trial.
The most recent Phase 3 data — from the TRIUMPH-4 trial published December 2025 — pushed those numbers further still. In 445 adults with obesity and knee osteoarthritis followed for 68 weeks, retatrutide 12 mg produced −28.7% body weight — an average of 71.2 lbs lost. The 9 mg dose produced −26.4% (−64.1 lbs). WOMAC knee pain scores also improved by up to 75.8%, a secondary finding with significant implications for patients who struggle to exercise due to joint pain.
[INTERNAL-LINK: semaglutide vs tirzepatide comparison → GLP-1 medication comparison guide]
How Does Retatrutide Compare to Semaglutide and Tirzepatide?
The comparison across the three drug classes tells a clear story. Semaglutide (Ozempic, Wegovy) produces approximately 14.9% body weight loss at 68 weeks. In a 2025 head-to-head randomized trial published in NEJM, tirzepatide outperformed semaglutide with 20.2% versus 13.7% — confirming dual agonism’s advantage. Retatrutide’s Phase 3 TRIUMPH-4 data at 28.7% places it in a different category entirely.
| Feature | Semaglutide | Tirzepatide | Retatrutide |
|---|---|---|---|
| Mechanism | GLP-1 | GLP-1 + GIP | GLP-1 + GIP + Glucagon |
| Max Weight Loss (trials) | ~14.9% | ~22.5% | ~28.7% |
| Liver Fat Reduction | Moderate | Moderate–High | Up to −82% |
| Direct Energy Expenditure Boost | No | No | Yes (glucagon) |
| Systolic BP Reduction | Modest | Modest | Up to −14 mmHg |
| FDA Status | Approved | Approved | Phase 3 (~2027) |
A Surprising Benefit: Retatrutide and Liver Health
One finding from Phase 2 research that doesn’t get enough attention: retatrutide dramatically improved liver fat in patients with metabolic dysfunction-associated steatotic liver disease (MASLD — formerly called NAFLD). In a Phase 2a sub-study published in Nature Medicine (Sanyal et al., 2024), the 8 mg and 12 mg doses reduced hepatic lipid content by 81–82% at 24 weeks versus just 0.3% in the placebo group.
Clinical context: At The Functional Weightloss, we regularly see patients with elevated ALT/AST or diagnosed fatty liver alongside their weight concerns. The liver data from retatrutide is one of the most compelling aspects of this compound for our patient population — it suggests the benefits go well beyond the number on the scale. Most interventions barely move hepatic steatosis. The glucagon component here is doing something mechanistically distinct.
[INTERNAL-LINK: fatty liver and metabolic syndrome → guide to MASLD and weight loss]
What Are the Side Effects of Retatrutide?
Retatrutide’s side effect profile is consistent with other GLP-1 class medications — predominantly gastrointestinal, dose-dependent, and concentrated during the dose escalation phase. In Phase 2 trials, nausea was reported in 43.2% of the 12 mg group versus 10.7% of placebo; vomiting in 20.9% versus 0%; diarrhea in 33.1% versus 13.4% (Jastreboff et al., NEJM, 2023). Discontinuation due to side effects was low — approximately 6% in the 12 mg group.
In my clinical experience, the single most important factor in GI tolerability is how slowly you titrate. Starting at a lower dose and extending the escalation schedule by 2–4 weeks dramatically reduces side effect burden. A 2025 body composition substudy in Lancet Diabetes & Endocrinology (Coskun et al.) confirmed via DXA imaging that fat mass was the predominant source of weight reduction — though adequate protein intake and resistance training remain non-negotiable to protect lean mass during any significant weight loss intervention.
[INTERNAL-LINK: managing GLP-1 side effects → guide to reducing nausea on peptide therapy]
Who Is a Good Candidate for Retatrutide?
Based on the trial populations and the mechanistic profile, retatrutide is most compelling for patients with BMI ≥30 — or BMI ≥27 with at least one comorbidity (T2D, hypertension, dyslipidemia, MASLD, joint disease). The triple mechanism makes it particularly powerful for metabolic syndrome — elevated fasting glucose, high triglycerides, low HDL, abdominal obesity, and elevated blood pressure. Retatrutide’s three-receptor approach addresses all five markers simultaneously. It’s also the strongest option for patients with fatty liver, and for prior GLP-1 incomplete responders who plateaued on semaglutide or tirzepatide before reaching goal.
Retatrutide is not yet FDA-approved as of June 2026. The TRIUMPH Phase 3 program is ongoing; an NDA filing is expected in late 2026 with potential approval in Q1–Q2 2027. Provider-supervised compounding access is available now.
Want physician-supervised access to retatrutide? Metabolic Regen MD offers compounded retatrutide under licensed provider oversight with full metabolic workup and personalized dosing protocol. Learn more at Metabolic Regen MD →
[INTERNAL-LINK: current peptide options available now → GLP-1 and peptide programs at The Functional Weightloss]
Baseline Labs Dr. Nguyen Recommends Before Starting
Before starting retatrutide — or any GLP-1/triple agonist — I run a targeted functional medicine panel on every patient. These labs establish your baseline, flag contraindications, and give us the data to track your metabolic transformation objectively. You can order most of these at-home without a doctor’s order through Private MD Labs (use code MICHAEL166 for 15% off) — I recommend running your panel before your first provider consultation so your prescriber has the data on day one.
| Lab Test | Why It Matters |
|---|---|
| HbA1c + Fasting Glucose | Glycemic baseline; required before titrating a glucose-lowering agent |
| Comprehensive Metabolic Panel | Kidney and liver function — both safety checkpoints for this drug class |
| Lipid Panel with ApoB | Cardiovascular risk baseline; retatrutide dramatically improves this panel |
| TSH | GLP-1 class carries thyroid warning; undiagnosed hypothyroidism is a common weight driver |
| Fasting Insulin + HOMA-IR | Quantifies insulin resistance — tells us how aggressive to be with the protocol |
| Vitamin B12 + Lipase | B12 absorption can decline with reduced intake; lipase is a pancreatic safety baseline |
Order your metabolic panel through Private MD Labs (code MICHAEL166 for 15% off) →
Supplements Dr. Nguyen Recommends Alongside Retatrutide
Retatrutide does the heavy lifting on weight loss — but how you support your body during aggressive caloric restriction determines how much comes from fat versus lean muscle. These are my recommendations for every patient on a triple agonist: protein at 1.2–2.0 g/kg/day (the single most important variable for lean mass preservation); creatine monohydrate at 3–5 g/day (clinically validated for lean mass retention during caloric restriction — one of the most underused supplements in weight loss medicine); magnesium glycinate at 200–400 mg/day (supports muscle function, insulin sensitivity, BP, and sleep); methylcobalamin B12 at 500–1,000 mcg/day (GI side effects and reduced food intake can impair B12 over months); and vitamin D3 + K2 (deficiency is extremely common in obese patients and matters significantly for bone and muscle during major weight loss).
I source pharmaceutical-grade versions of all of these through my Thorne dispensary — third-party tested, no fillers, consistent formulations. Shop Dr. Nguyen’s Thorne dispensary →
How to Access Retatrutide Today
Option 1 — Provider-Supervised Compounding (Recommended): Licensed functional medicine and telehealth providers can prescribe compounded retatrutide through 503A/503B compounding pharmacies while the drug completes its approval pathway. Metabolic Regen MD offers physician-supervised access with full metabolic workup, ongoing lab monitoring, and personalized dose titration.
Option 2 — Research Access: For qualified researchers, Elite Biologix supplies research-grade GLP-1 peptides at ≥98% purity, verified by third-party HPLC and mass spectrometry.
Frequently Asked Questions About Retatrutide
Is retatrutide FDA-approved?
No. As of June 2026, retatrutide is still in Phase 3 clinical trials under Eli Lilly’s TRIUMPH program. TRIUMPH-4 data showed −28.7% body weight loss at 68 weeks (December 2025). An NDA filing is expected in late 2026 with potential FDA approval in Q1–Q2 2027. Access in the interim requires physician prescription through compounding channels.
How does retatrutide compare to Ozempic or Wegovy?
Retatrutide consistently outperforms semaglutide (Ozempic/Wegovy) in clinical data. Semaglutide produces approximately 14.9% body weight loss at 68 weeks; retatrutide produces 28.7% at a similar timeframe — roughly double. The difference comes from retatrutide’s additional GIP and glucagon receptor activation, which semaglutide does not have.
What makes retatrutide different from tirzepatide (Mounjaro/Zepbound)?
Tirzepatide activates GLP-1 and GIP receptors — a meaningful advance over semaglutide. Retatrutide adds glucagon receptor activation on top, which directly increases energy expenditure and drives hepatic fat oxidation. In Phase 2 data, retatrutide 12 mg produced −24.2% vs tirzepatide’s −22.5% at comparable timeframes, and Phase 3 data suggests that gap widens with longer treatment duration.
What are the main side effects?
Primarily gastrointestinal — nausea (43.2% at 12 mg), vomiting (20.9%), diarrhea (33.1%), and constipation (25%). These are dose-dependent and most pronounced during escalation. Slower titration schedules significantly reduce GI burden. Discontinuation rates in Phase 2 were approximately 6% at the therapeutic dose.
Do I need labs before starting retatrutide?
Yes — I consider baseline labs non-negotiable. At minimum: HbA1c, fasting glucose, CMP, lipid panel with ApoB, TSH, CBC, fasting insulin, HOMA-IR, vitamin B12, and lipase. Order at-home through Private MD Labs (code MICHAEL166 for 15% off).
Does retatrutide help with liver disease?
Yes — Phase 2a data published in Nature Medicine (2024) showed the 12 mg dose reduced liver fat by 82% at 24 weeks, with the glucagon receptor mechanism specifically driving hepatic fat oxidation. This is particularly significant for patients with MASLD/fatty liver alongside obesity.
Is Retatrutide the Future of Weight Loss Medicine?
The Phase 3 TRIUMPH-4 data isn’t just incrementally better than what came before — it’s a category shift. A drug that reliably produces 25–29% body weight loss, simultaneously reduces liver fat by 82%, drops blood pressure by 14 mmHg, and improves lipids by nearly 27% represents a meaningful new ceiling on what’s achievable for patients who’ve struggled with obesity for years.
But medication is only as powerful as the foundation it’s built on. The patients who see the most lasting results — with any pharmacological support — are those who’ve built metabolic resilience: stable sleep, adequate protein, muscle mass, and balanced labs. Retatrutide will accelerate results. The foundation determines whether those results last.
Ready to start? Start with a consultation at Metabolic Regen MD for physician-supervised compounded retatrutide — or run your baseline metabolic panel first through Private MD Labs (code MICHAEL166). Support your body with pharmaceutical-grade supplements from Dr. Nguyen’s Thorne dispensary. For research-grade compounds, visit Elite Biologix.
[INTERNAL-LINK: book a consultation → contact/booking page for The Functional Weightloss]
Sources
- Jastreboff AM et al. Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. N Engl J Med. 2023;389(6):514–526. PMID 37366315
- Alnaqbi H et al. Efficacy and safety of retatrutide for obesity: systematic review and meta-analysis. PMC. 2025. PMID 40291085
- Sanyal AJ et al. Triple hormone receptor agonist retatrutide for MASLD: a randomized phase 2a trial. Nature Medicine. 2024;30:2037–2048. DOI: 10.1038/s41591-024-03018-2
- Rosenstock J et al. Retatrutide for type 2 diabetes: a randomised, phase 2 trial. The Lancet. 2023. DOI: 10.1016/S0140-6736(23)01053-X
- Coskun T et al. Effects of retatrutide on body composition in type 2 diabetes. Lancet Diabetes & Endocrinology. 2025. DOI: 10.1016/S2213-8587(25)00092-0
- Retatrutide lipid and cardiovascular risk profile. European Heart Journal Supplements. ESC 2024. DOI: 10.1093/eurheartj/ehae666.1501
- Effects of once-weekly retatrutide on metabolic markers: meta-analysis. PMC. 2024. PMCID 11420505
- Eli Lilly. TRIUMPH-4 Phase 3 obesity trial results. PR Newswire. December 2025. Press Release
This article is written by Dr. Michael Nguyen, PharmD, BSPharm, for educational and informational purposes only. It does not constitute medical advice. Retatrutide is an investigational drug not yet approved by the FDA. Consult a licensed healthcare provider before starting any peptide therapy or weight loss medication.